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Abstract
Background: Our goal was to examine how various aspects of a gene signature influence the success of
developing multi-gene prediction models. We inserted gene signatures into three real data sets by altering the
expression level of existing probe sets. We varied the number of probe sets perturbed (signature size), the fold
increase of mean probe set expression in perturbed compared to unperturbed data (signature strength) and the
number of samples perturbed. Prediction models were trained to identify which cases had been perturbed.
Performance was estimated using Monte-Carlo cross validation.
Results: Signature strength had the greatest influence on predictor performance. It was possible to develop almost
perfect predictors with as few as 10 features if the fold difference in mean expression values were > 2 even when
the spiked samples represented 10% of all samples. We also assessed the gene signature set size and strength for
9 real clinical prediction problems in six different breast cancer data sets.
Conclusions: We found sufficiently large and strong predictive signatures only for distinguishing ER-positive from
ER-negative cancers, there were no strong signatures for more subtle prediction problems. Current statistical
methods efficiently identify highly informative features in gene expression data if such features exist and accurate
models can be built with as few as 10 highly informative features. Features can be considered highly informative if
at least 2-fold expression difference exists between comparison groups but such features do not appear to be
common for many clinically relevant prediction problems in human data sets.
Background
Gene expression data are commonly used to develop
multi-gene prediction models for various clinical classifi-
cation problems. Several gene expression-based multi-
variate prognostic and treatment sensitivity predictors
have been developed for breast cancer and numerous
other “gene signatures” have been reported to predict
specific biological states including pathway activity and
mutation status of p53, BRCA, PIK3 and other genes in
cancer [1-9]. However, many genomic predictors yielded
low accuracy in independent validation [10-14]. It also
seems apparent that some classification problems are
easier to solve than others in the mRNA expression
space. For example, it is straightforward to construct
accurate classifiers for breast cancer that predict estro-
gen-receptor (ER) status or histologic grade due to the
large scale gene expression differences that exist
between ER-positive and -negative or low grade versus
high grade cancers [14-17]. Many of the empirically
developed first generation prognostic and predictive
gene signatures for breast cancer derive their predictive
value from recognizing molecular equivalents of ER sta-
tus and tumor grade. This is because prognosis, drug
response rates and even p53, PI3K or BRCA mutation
status are not evenly distributed between ER-positive
and -negative breast cancer [18]. When clinically more
homogeneous subtypes of breast cancers are analyzed, it
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good performance metrics [19].
Supervised classification models are developed
through comparison of groups of samples that differ in
clinical outcome of interest. The first step typically
involves identification of informative probe sets/genes (i.
e. features) that are differentially expressed between the
groups. Next, these informative features are considered
as variables to train a multivariate classification model.
Intuitively, the predictive performance of classifiers must
depend on the number of informative features, the mag-
nitude of difference in feature expression levels between
the groups of interest, and the number of informative
cases in each group. These critical parameters are
expected to vary from classification problem to classifi-
cation problem and from data set to data set. However,
it is not well understood how each of these components
influence the success of the classifier development pro-
cess and what the minimum requirement to develop
successful predictors might be.
The goal of this analysis was to take public breast can-
cer gene expression datasets, spike these with a series of
artificial “gene signatures” and assess how well these
spiked-in gene signatures could be recovered and used
to develop a multi-gene classifier to predict “spiked-in”
status of a sample. The artificial gene signatures con-
sisted of real probe sets whose expression values were
increased (i.e. spiked) with a constant. The extent of
perturbation varied over a broad range for three key
parameters: (i) the number of samples perturbed (i.e.
informative cases), (ii) the number of probe sets
included in the artificial signature (i.e. signature size),
and (iii) the fold increase in mean expression value for
the spiked probes (i.e. signature strength). To place our
findings into context, we also calculated gene signature
size and strength for nine different real-life clinical pre-
diction problems in six different data sets.
Methods
Data sets
We used 3 publically available human breast cancer
gene expression data sets each generated with Affyme-
trix U133A gene chips. These included the Microarray
Quality Control Consortium (MAQC II) breast cancer
data (n = 233, Gene Expression Omnibus [GEO acces-
sion number GSE 16716] [20], the TRANSBIG data set
[n = 199, GSE 7390] [3] and the Wang et al data set [n
= 286, GSE 2034] [2]. Each data set was analyzed sepa-
rately using identical analysis plan to assess consistency
of findings. The individual Affymetrix CEL files were
MAS5 normalized to a median target array intensity of
600 and expression values were transformed to log base
2 values using the Bioconductor software http://www.
bioconductor.org.
Perturbing of probe set expression values
We randomly selected s samples (s = 10, 15, 20, 25, 30,
40, 60, 80, 100) to be perturbed in each data set. In the
classification exercise described below, these s perturbed
samples represent one class and the remaining samples
in the dataset represent the other class. For each s sample
set, we randomly selected g probe sets (g = 10, 15, 20, 25,
30, 50, 100, 250, and 500) to represent the informative
features (i.e. spiked gene signature). We altered the nor-
malized, log2-transformed expression values of each g
p r o b es e t sb ya d d i n gt h es a m ec constant (c =0 ,0 . 5 ,1 ,
1.2, 1.5, 2, 3, 4). This is equivalent to multiplying the ori-
ginal scale value by 2
c. So, c = 0 corresponds to unper-
turbed data, c = 1.0 corresponds to a 2-fold increase and
c = 2 corresponds to a 4-fold increase. By perturbing
probe sets only in the s randomly selected samples, we
are generating gene signatures between the two classes of
increasing size and strength. We also created perturbed
data sets where the probe sets were perturbed with ran-
domly picked constants within brackets of c values using
uniform distribution including c = (0.0 to 0.5), (0.50 to
1.0), (1.00 to 1.2), (1.2 to 1.5), (1.5 to 2.0), (2.0 to 2.5),
(2.5 to 3.0), and (3.0 to 4.0). We repeated the entire per-
turbation process 20 times for each possible s(sample)-g
(probe set)-c(constant) combination in all 3 data sets.
Classifier model building
We used t-tests to compare the spiked cases with the rest
of the cases to identify differentially expressed probe sets
among all probe sets represented on the arrays. We
ranked all probe sets by p-value and used the top n fea-
tures (n = 10, 25, 50, 100 and 500) to construct multivari-
ate prediction models using Diagonal Linear
Discriminant Analysis (DLDA) for each s-g-c combina-
tion [4,19,21]. During model building we used the known
perturbation status of the samples to train the models.
We tracked how many of the spiked probe sets (i.e.
truly informative features) were included in the top n
features in each iteration of the t-test. As reference
point for these observations, we also used the same
method to identify informative probe sets for 9 real clin-
ical classification problems. First we compared ER-posi-
tive with ER-negative breast cancers, then cancers with
pathologic complete response (pCR) to chemotherapy
versus lesser response (RD), and subsequently cases with
pCR versus RD among ER-negative cancers (GEO data
set: GSE 16716). During these analyses we kept the
overall sample sizes and the proportion of informative
cases identical for each 3 comparisons in order to stan-
dardize the power of the analysis. The smallest sample
size was the comparison of pCR versus RD among ER-
negative cancers that included 91 cases (pCR = 41, RD
= 50). Therefore, we only used a randomly sampled sub-
set of 91 cases from the total of 233 MAQCII cases for
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RD” comparisons and also fixed the proportion of infor-
mative cases to 41 versus 50 for each comparisons. To
obtain further reference values to interpret our spiked-
in simulation results we also generated lists of informa-
tive probe sets to distinguish cancers that relapsed with
those that did not relapse (GSE 7390, GSE 2034 and
GSE11121), inflammatory from non-inflammatory breast
cancer (GSE 22597), p53-mutant from p53-normal (GSE
3494) and PIK3CA-mutant from PIK3-normal cancers
[9]. These analyses were performed separately for ER-
positive and ER-negative cancers in each data set in
order to avoid contamination by phenotype-related
genes. False discovery rates were estimated using the
fdrtool software package [22].
Assessment of prediction models
Our goal was to predict which samples were perturbed.
We built prediction models with the top 10, 25, 50, 100,
500 features selected by t-test and ranked by p-value
within each s-g-c combination (N = 9(s)×9 ( g)×8 ( c)×
20 (replicates) = 12, 960 data sets). To estimate predic-
tive performance, we performed stratified 3-fold Monte
Carlo Cross-Validation (MCCV) with 100 iterations.
During cross validation, we randomly selected 2/3 of the
data to train the model and the remaining samples were
used as a test set. This selection process was done sepa-
rately within the spiked and non-spiked groups in order
to maintain the same proportion of perturbed and
unperturbed cases in the training and testing sets. New
feature selection was performed during each iteration.
The classification process was assessed by two metrics:
(i) the area above the receiver operating characteristic
curve (AAC) which is the complement of the area under
the curve (AUC) (AAC = 1-AUC) and (ii) the spiked
probe recovery rate. When the total number of spiked
probe sets is less than the number of features included
in the classifier, we computed the recovery rate by divid-
ing the number of correctly selected spiked probes
included in the model by the number of all spiked
probes. If the number of spiked probes was greater than
the number of features included in the classifier we cal-
culated the recovery rate by dividing the number of cor-
rectly selected spiked probe sets by the number of all
features included in the classifier. The ability to include
the perturbed/spiked probe sets in the classifier is criti-
cal for producing a model with good predictive accuracy
(i.e. performance). Thus the rate at which spiked probe
sets are included in the classifier (i.e., “recovered”)i sa
useful metric for evaluating the classification process.
An R-code package has been developed to run the
complete probe set spiking, model building and predic-
tor evaluation process and is included in Additional File
1.
Results
The effects of sample size and signature strength on
spiked-in gene recovery
First, we examined the spiked probe set recovery rates
as function of signature strength and number of spiked
samples. Figure 1 shows the probe set recovery rates
when the number of spiked probes was set to 10 while
we varied the number of spiked-in samples from s =1 0
to 100 (4.3% - 43% of all samples, MAQC-II data set n
= 233) and the fold change of the spiked probe sets
over c = 0.5, 1.0, 1.2, and 1.5. Fold change (i.e. signature
strength) had the greatest effect on feature recovery
rate. With c = 1.5, the average recovery rate was > 60%
(range: 30-80%) even when only 10 samples were spiked.
When the spiked sample size reached 40 (17% of all
samples) the average recovery rate increased to > 80%
(range: 70-100%). On the other hand, when the c was a
modest 0.5, the recovery rate remained low, around 40%
even when the spiked-in sample size was 100. Similar
trends were seen when 50 or 500 probe sets were spiked
(Supplementary Results). These observations were con-
sistent across all 3 data sets and indicate that fold
increase in the expression value of informative probe
sets has a major influence on feature recovery rate.
Probe sets with less than 1.5-fold difference in mean
expression values between comparison groups are diffi-
cult to identify as informative features.
The effects of sample size and signature strength on
classifier performance
Next, we examined how increasing the number of per-
turbed cases and the fold difference in spiked probe sets
influence predictor performance. The classifier perfor-
mance improved dramatically as the signature strength
increased. The predictors reached almost perfect accu-
racy at c = 1.0 (2-fold change) when 20-25 samples (9-
11% of samples) were spiked (Figure 2). Increasing the
number of spiked cases gradually improved model per-
formance when the c was a modest 0.5, but even at
sample size of 100 (43% of all samples), the AAC was
0.2. The same was observed in all 3 data sets and over a
broad range of spiked probe sets (g = 10-500), results
were least sensitive to the number of features included
in the classification models (Additional File 2).
We also examined the more realistic scenario when
we altered the expression of the selected probe sets over
a range of fold change that differed from probe set to
probe set but remained within brackets of pre-specified
maximum c including (0.0-0.5), (0.50-1.0), (1.00-1.2) and
(1.20-1.5). The individual c constants that were added to
the log2 expression values of each of the probe sets
selected for spiking were randomly picked from all pos-
sible values within a given bracket. This experiment
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slightly reduced performance at signature strength
below 2-fold expression change (Supplementary Results).
Essentially perfect predictors could be constructed once
the spiked-in sample size reached 10% of the study
population and the signature strength bracket was ≥
1.0-1.2.
Effect of signature size on prediction accuracy
We also examined how the signature size, the number
of perturbed probe sets, affects prediction performance.
Since predictive accuracy rapidly reached a plateau
when the fold increase in the expression of informative
probe sets reached 2 (i.e., when c reached 1) (Figure 2),
for this analysis we fixed c at 0.5. We varied the number
of samples that were perturbed (s = 10-100) and the
number of spiked probe sets from 10 to 100 but kept
the feature set size used for model building at 100. Pre-
dictive performance improved gradually as the signature
size increased at each sample size level (Figure 3). Pre-
dictive performance also improved as the sample size of
perturbed cases increased. However, increasing the fea-
ture set size in a model led to modestly deteriorating
performance when the number of informative probe sets
was small and the signature strength was low, due to
inclusion of noise in the model. As the number of truly
informative probe sets converges towards the number of
features included in the model, the performance
improves rapidly even at small sample sizes.
To further explore the effect of noise (i.e. uninformative
features included in the model) on predictor performance,
we kept the number of spiked probes at 10 and set the the
predictive model size at 100 features. Figure 4 shows that
increasing the signature strength dramatically improves
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Figure 1 Spiked probe set recovery rates as function of informative samples size and signature strength.B o t h ,t h en u m b e ro fs p i k e d
probes (genes) and the number of features included in the predictor model were set to 10. The solid lines indicate the average recovery rates
and the dots represent results from the 20 individual iterations. Results from the MAQC-II data set (n = 233) are shown. The “c” value which is
the log2 fold-change takes on the values 0.5, 1.0, 1.2 and 1.5.
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informative features are included in the model. For exam-
ple, if a gene signature consists of 10 probe sets each of
which has a 4-fold increase in expression in a subset of
4.3% (n = 10) of the entire study population a highly accu-
rate predictor could be built with an AAC of 0.2. These
results indicate that the most critical determinant of model
performance is signature strength. If the magnitude of
expression difference is ≤ 2 fold and the true signature size
is small, model performance depended strongly on the
number of cases that were perturbed and on the number of
non-informative probe set included in the model. Greater
than 30% of samples need to be informative in order to
develop and train a model with an AAC around 0.2-0.3 if
the true signature includes only 10 probe sets with a 2-3
fold difference but also includes a large number of spur-
iously selected, non-informative features (90 of 100).
Gene signature size and strength for real clinical
prediction problems
Genomic classifiers developed to predict clinical out-
come in breast cancer usually yield substantially lower
AUC values than what we could achieve in our simula-
tion experiments [13,19,20]. This suggests that real life
clinical classification problems often involve low level
expression differences in a modest number of genes (i.e.
< 2 fold difference in < 10 genes). To estimate signature
size and strengths for various real-life prediction pro-
blems we calculated fold change differences for the top
100 most differentially expressed probe sets between (i)
ER-positive and ER-negative cancers, (ii) highly che-
motherapy sensitive (i.e. those who achieved pCR) and
less sensitive cancers and (iii) chemotherapy sensitive
versus less sensitive cancers among ER-negative breast
cancers using a standardized sample size of 91 and a
Gene:10, Feature:10, c:0.5
SpikedInSample
M
C
C
V
 
m
e
a
n
 
A
A
C
0 2 04 06 08 0 1 0 0
0
.
0
0
.
2
0
.
4
0
.
6
Gene:10, Feature:10, c:1
SpikedInSample
M
C
C
V
 
m
e
a
n
 
A
A
C
02 0 4 0 6 0 8 0 1 0 0
0
.
0
0
.
2
0
.
4
0
.
6
Gene:10, Feature:10, c:1.2
SpikedInSample
M
C
C
V
 
m
e
a
n
 
A
A
C
0 2 04 06 08 0 1 0 0
0
.
0
0
.
2
0
.
4
0
.
6
Gene:10, Feature:10, c:1.5
SpikedInSample
M
C
C
V
 
m
e
a
n
 
A
A
C
02 0 4 0 6 0 8 0 1 0 0
0
.
0
0
.
2
0
.
4
0
.
6
Figure 2 Classifier performance as function of informative sample size and signature strength. Both, the number of spiked probes and
the number features included in the predictor model were set to 10. The solid lines indicate the average area above the ROC curve (AAC) from
Monte Carlo Cross Validation (MCCV). The smaller the AAC the more accurate the predictor is. The dots represent results from the 20 individual
iterations of the analysis performed on the MAQC-II data set (n = 233). The “c” value which is the log2 fold-change takes on the values 0.5, 1.0,
1.2 and 1.5.
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Page 5 of 10fixed proportion of informative cases for each of these
comparisons. In the ER-positive versus -negative compar-
ison, the top 10 probe sets all had > 2 fold mean expres-
sion difference with very low FDR. In the pCR versus
lesser response comparison without stratification by ER
status, the top 10 list included only 3 genes that had > 2
fold difference but all the rest had expression difference
between 1-2 fold and all features had low FDR. When the
same analysis was restricted to ER-negative patient only,
the top 10 differentially expressed list contained no genes
with ≥ 1.2 fold expression difference and FDR values
were high suggesting that many of these may not be truly
informative. Even after extending the differentially
expressed list to include the top 100, it contained only 2
probe sets whose expression difference was ≥ 1.2 and < 2
(Table 1). We found similarly small and weakly informa-
tive signatures for 6 other prediction problems and the
associated FDR values were high (Table 2).
These observations confirm that for easier classifica-
tion problems, such as ER status prediction, a large
number of informative probe sets exist and these show
large fold differences but for all other prediction pro-
blems that we tested the number of informative features
was low and feature strength was modest at best.
Discussion
T h eg o a lo ft h i sp r o j e c tw a st oa s s e s sh o wg e n es i g n a -
ture size (i.e. the number of informative probe sets), sig-
nature strength (i.e. fold difference in the mean
expression of the informative probe sets between the
comparison groups) and the number of informative
cases in a data set influence the success of developing
multi-gene prediction models. We also examined how
model performance deteriorates as increasing amount of
noise (i.e. un-informative features) are included in a
model. To study these variables we altered the true
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Figure 3 Classifier performance is influenced by signature size, the number of informative cases and the number of features included
in the prediction model. The numbers of spiked probes were 10, 25, 50 and 100 and the number of features included in the prediction model
was set to 100. Log2 fold-change ("c”) was set to 0.5. The solid lines indicate the average area above the ROC curve (AAC) from Monte Carlo
Cross Validation (MCCV), the dots represent results from the 20 individual iterations of the analysis performed on the MAQC-II data set (n = 233).
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Page 6 of 10expression values of randomly selected genes in real
human gene expression data sets. What motivated this
research was to find out what signal elements in the
genomic model building process may explain the sub-
stantial difficulty to find clinically relevant multi-gene
predictors for many cancer classification problems.
Our results demonstrate that signature strength had
the greatest influence on the success of model building
followed by the size of the gene signature and the num-
ber of informative cases. Predictors tolerated large
amounts of noise included in the model as long as it
also contained numerous strong informative features. It
was remarkably easy to develop almost perfect predic-
tors with as few as 10 informative probe sets if the fold
difference in the expression values of these probe sets
was > 2.0, even if the informative samples represented <
10% of the total sample size. These simulated results are
better than the reported performance of the majority of
empirically developed genomic outcome predictors
[10,11,23-27]. To examine the causes of this discre-
pancy, we calculated the number of informative probe
sets and their fold difference (i.e signature strength) for
9 different real clinical prediction problems in 6 publi-
cally available breast cancer data sets. We only found
sufficiently large and strong predictive signature for one
prediction problem, to distinguish ER-positive from ER-
negative breast cancers (87 features with ≥ 2 fold differ-
ence). Surprisingly, there was no strong signature for
the clinically more relevant problems of predicting che-
motherapy sensitivity among ER-negative cancers (6 of
the top 10 genes had < 2 fold difference and only 9 of
the top 100 genes had fold difference > 2 but all were
less than 4.0 and FDR was high) and for a series of
other diagnostic or mutation prediction problems.
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Figure 4 Classifier performance as function of signature strength and informative sample size when redundant features are also
included in the model. The number of spiked probes was set to 10 and the number of features included in the predictor was set to 100. The
informative sample sizes were 10, 30, 60, 100 and the log2 fold increases (i.e., c values) were, 0.5, 1.0, 1.2, 1.5, 2.0, 3.0, 4.0. The solid lines indicate
the average area above the ROC curve (AAC) from Monte Carlo Cross Validation (MCCV), the dots represent results from 20 iterations of the
analysis performed on the MAQC-II data set (n = 233).
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efficiently identify highly informative features in com-
plex gene expression data sets if such features exist. Fea-
tures can be considered highly informative if at least a
2-fold expression difference exists between the means of
the two comparison groups. With as few as 10 such fea-
tures almost perfect classification models can be built.
However, highly informative features do not appear to
be common for many clinically relevant prediction pro-
blems. There may be several biological explanations for
this. First, the dynamic regulation of the expression of
the thousands of mRNA species in cancer cells is not
well understood. What level of change in mRNA expres-
sion leads to functionally important consequences (e.g.
altered chemotherapy sensitivity) is unknown and it is
likely to be different from gene to gene. Some physiolo-
gical variables are very tightly regulated, a 10% change
in serum sodium levels can lead to life threading conse-
q u e n c e sw h e r e a sv a r i a b l e ss u c ha sh e a rr a t eo rb l o o d
pressure have broad normal dynamic range. It is likely
that similar phenomena also occur in the mRNA world
and a 15-50% percent change in the expression level of
some mRNA species may result in functional conse-
quences but such genes would not define strong predic-
tive features. Also importantly, protein expression levels
correlate with mRNA expression only moderately and
protein levels or posttranslational changes in proteins
may represent the functional activity of biological path-
ways more accurately than mRNA levels. Structural var-
iations in genes at the DNA level can profoundly alter
the functional activity of proteins such mutations may
also not cause large scale changes in mRNA expression.
While our spike-in simulation studies yielded much
useful information, they are limited in several respects.
In real datasets expression values responding to regula-
tory influences would presumably change in a coordi-
nated rather than random fashion. However, the degree
of change and number of genes involved in a particular
coordinated change may be relatively small and thus not
conducive for use in a predictive model. Overall these
observations are consistent with previous sensitivity ana-
lysis of prediction models that have highlighted the vul-
nerability of predictors to feature strength [28-30].
Conclusions
In summary, our findings suggest that in the currently
available mRNA gene expression data sets of breast can-
cer there may not be enough highly informative genes
to develop clinically useful genomic classifies to predict
certain types of clinical outcomes. We recognize that
the sample sizes that are currently available for analysis
are modest, and particularly small analyses are per-
formed in disease subsets. Our simulation results sug-
gest that predictor performance in the absence of strong
predictive signatures may improve only modestly even if
sample size increases. We developed an R software code
package that could be used to estimate the number of
informative probe sets, based on gene spiking, that is
needed for accurate model building in any experimental
data set. This could be used as a tool to estimate the
Table 1 Fold difference in the expression values of informative probe sets for 3 different clinical prediction problems
assessed in the same breast cancer data set (GEO GSE 16716)
ER+ versus ER-
1 pCR versus RD
2 pCR versus RD in ER- cancers only
3
Feature # 10 Feature # 100 Feature # 10 Feature # 100 Feature # 10 Feature # 100
FDR adjusted p-value 4.71E-12 3.26E-07 0.004 0.0205 0.4 0.68
Fold difference
4
< 0 . 5 0006 4 5 9
≥0.5 - < 1.0 0 13 3 43 2 32
≥1.0 - < 1.2 0 81 1 5 4 7
≥1.2 - < 1.5 0 18 2 17 0 1
≥1.5 - < 2.0 0 18 2 11 0 1
≥ 2.0 - < 3.0 62 82 8 00
≥ 3.0 - < 4.0 31 200 0 0
≥ 4.0 1300 0 0
1Random sample of 41 ER Positive and 50 ER Negative Samples
2Random sample of 41 pathologic CR and 50 residual cancers regardless of ER status.
3Random sample of 41 pathologic CR and 50 residual cancers all ER Negative.
4Log2 Difference = abs(mean log2 intensity for group1 - mean log2 intensity for group 2) where “abs” is absolute value.
The numbers of probe sets with a given level of differential expression are shown for the 3 comparisons including (i) Estrogen Receptor (ER)-positive versus ER-
negative cancers, (ii) cancers with pathologic complete response (pCR) to chemotherapy versus lesser response (RD) and (iii) cases with pCR versus RD in ER-
negative cancers only. Probe sets with mean log2 transformed expression difference >1 between comparisons groups are highlighted in bold. FDR = false
discovery rate (i.e., proportion of genes detected to be informative which are not truly informative). FDR adjusted p-values (also known as FDR q-values) are the
estimated FDR values that would be incurred if the p-values associated with the selected genes were used as the threshold for significance (i.e., genes with that
p-value or a lower p-value were to be detected as informative). So for the Feature #10 column, the reported FDR adjusted p-value is the q-value associated with
the 10th highest ranked gene.
Hess et al. BMC Bioinformatics 2011, 12:463
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Page 8 of 10adequacy of a given data set to yield empirically derived
classifiers.
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Table 2 Fold difference in the expression values of informative probe sets for 6 different prediction problems in
different data sets.
Data set IBC versus Non-IBC p53 mutation versus normal PIK3 mutation versus normal
Receptor
status
ER-negative ER-positive ER-negative ER-positive ER-negative ER-positive
Phenotype IBC Non-IBC IBC Non-IBC mutation normal mutation normal mutation normal mutation normal
Pts # 19 vs 27 6 vs 31 44 vs 11 14 vs 31 8 vs 49 15 vs 57
Feature # 10 100 10 100 10 100 10 100 10 100 10 100
FDR q value 1.000 1.000 0.280 0.500 0.14 0.33 0.49 0.6 0.08 0.09 0.24 0.55
Fold difference
*
< 0.5 0 20 0 2 1 9 2 29 0 0 0 17
≥0.5 - < 1.0 4 55 1 41 1 37 5 47 1 23 6 50
≥1.0 - < 1.2 2 11 1 10 1 11 1 11 3 18 1 17
≥1.2 - < 1.5 3 12 4 18 2 15 1 9 4 21 2 10
≥1.5 - < 2.0 002 2 0 2 22 1 4 1 23 0 5
≥2.0 - < 3.0 0 1 2 9360 0 11 41 1
≥3.0 - < 4.0 1 1 0 0000 0 0100
≥4.0 0 0 0 0 000 0 0000
Data set WANG TRANSBIG Mainz
Receptor
status
ER-
negative
ER-
positive
ER-
negative
ER-
positive
ER-
negative
ER-
positive
Recurrence Yes No Yes No Yes No Yes No Yes No Yes No
Pts # 29 vs 50 29 vs 50 18 vs 45 23 vs 112 11 vs 20 30 vs 139
Feature # 10 100 10 100 10 100 10 100 10 100 10 100
FDR q value 0.2 0.26 0.004 0.02 0.820 0.91 0.010 0.03 0.47 0.58 0.01 0.03
Fold difference
*
< 0.5 2 35 3 68 2 26 1 26 1 13 3 59
≥0.5 - < 1.0 6 51 7 30 4 47 5 52 5 44 5 26
≥1.0 - < 1.2 0 7 0 2 3 21 2 12 0 5 1 3
≥1.2 - < 1.5 0 5 0 0 1 6 181 1 6 00
≥1.5 - < 2.0 1 1 0 0 0 0 122 1 7 12
≥2.0 - < 3.0 1 1 0 0 0 0 0 0 0 3 0 0
≥3 . 0 - < 4 . 00 0 0 0 0 0 001200
≥4.0 0000000 0 0000
*Log2 Difference = abs(mean log2 intensity for group1 - mean log2 intensity for group 2) where “abs” is absolute value.
The numbers of probe sets with a given level of differential expression are shown for the 6 comparisons. Analyses were performed separately for Estrogen
Receptor (ER)-positive and ER-negative cancers. IBC = inflammatory breast cancer, PI3K = Phosphatidylinositol-3 kinase, FDR = false discovery rate. The WANG,
TRANSBIG, Mainz data sets correspond to references 2, 3 and 28. Probe sets with mean log2 transformed expression difference >1 between comparisons groups
are highlighted in bold.
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